Abstract
The incidence of non-Hodgkin lymphomas increases with age. Non-pegylated liposomal formulations of doxorubicin (Myocet®) reduce systemic and cardiac toxicity especially in the elderly, who often have cardiac diseases. We treated 80 patients (mean age 70.9 years) with poor-risk diffuse large B-cell lymphoma with the R-COMP 21 regimen (Myocet® 50 mg/m2, cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg/m 2, prednisone 100 mg/day). In all, 82.5% and 13.7% patients showed complete and partial responses, respectively. Sixty-two of the 80 patients are alive and disease-free (77.5%), while 3/80 are alive with active disease and 15 patients (18.7%) have died (median follow-up: 31 months). The estimated probability of overall survival at 12/24 months from admission was 93.5/87.3%, respectively. There were no therapy-related cardiac events and the ejection fraction improved (from 51.6±6.9% to 54.2±3.9%). Grade 3-4 neutropenia occurred in 22% of patients. We concluded that Myocet® shows both efficacy and tolerability, mainly at the cardiac level.
| Original language | English |
|---|---|
| Pages (from-to) | 1222-1229 |
| Number of pages | 8 |
| Journal | Leukemia and Lymphoma |
| Volume | 52 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 2011 |
Fingerprint
Keywords
- B-cell lymphoma
- cardiac toxicity
- non-pegylated liposomal doxorubicin
- poor-risk patients
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Cite this
Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma. / Dell'Olio, Matteo; Potito Scalzulli, Rosario; Sanpaolo, Grazia; Nobile, Michele; Saverio Mantuano, Francesco; La Sala, Antonio; D'Arena, Giovanni; Miraglia, Eustachio; Lucania, Anna; Mastrullo, Lucia; Nicola, Cascavilla.
In: Leukemia and Lymphoma, Vol. 52, No. 7, 07.2011, p. 1222-1229.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma
AU - Dell'Olio, Matteo
AU - Potito Scalzulli, Rosario
AU - Sanpaolo, Grazia
AU - Nobile, Michele
AU - Saverio Mantuano, Francesco
AU - La Sala, Antonio
AU - D'Arena, Giovanni
AU - Miraglia, Eustachio
AU - Lucania, Anna
AU - Mastrullo, Lucia
AU - Nicola, Cascavilla
PY - 2011/7
Y1 - 2011/7
N2 - The incidence of non-Hodgkin lymphomas increases with age. Non-pegylated liposomal formulations of doxorubicin (Myocet®) reduce systemic and cardiac toxicity especially in the elderly, who often have cardiac diseases. We treated 80 patients (mean age 70.9 years) with poor-risk diffuse large B-cell lymphoma with the R-COMP 21 regimen (Myocet® 50 mg/m2, cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg/m 2, prednisone 100 mg/day). In all, 82.5% and 13.7% patients showed complete and partial responses, respectively. Sixty-two of the 80 patients are alive and disease-free (77.5%), while 3/80 are alive with active disease and 15 patients (18.7%) have died (median follow-up: 31 months). The estimated probability of overall survival at 12/24 months from admission was 93.5/87.3%, respectively. There were no therapy-related cardiac events and the ejection fraction improved (from 51.6±6.9% to 54.2±3.9%). Grade 3-4 neutropenia occurred in 22% of patients. We concluded that Myocet® shows both efficacy and tolerability, mainly at the cardiac level.
AB - The incidence of non-Hodgkin lymphomas increases with age. Non-pegylated liposomal formulations of doxorubicin (Myocet®) reduce systemic and cardiac toxicity especially in the elderly, who often have cardiac diseases. We treated 80 patients (mean age 70.9 years) with poor-risk diffuse large B-cell lymphoma with the R-COMP 21 regimen (Myocet® 50 mg/m2, cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg/m 2, prednisone 100 mg/day). In all, 82.5% and 13.7% patients showed complete and partial responses, respectively. Sixty-two of the 80 patients are alive and disease-free (77.5%), while 3/80 are alive with active disease and 15 patients (18.7%) have died (median follow-up: 31 months). The estimated probability of overall survival at 12/24 months from admission was 93.5/87.3%, respectively. There were no therapy-related cardiac events and the ejection fraction improved (from 51.6±6.9% to 54.2±3.9%). Grade 3-4 neutropenia occurred in 22% of patients. We concluded that Myocet® shows both efficacy and tolerability, mainly at the cardiac level.
KW - B-cell lymphoma
KW - cardiac toxicity
KW - non-pegylated liposomal doxorubicin
KW - poor-risk patients
UR - http://www.scopus.com/inward/record.url?scp=79959582374&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79959582374&partnerID=8YFLogxK
U2 - 10.3109/10428194.2011.572321
DO - 10.3109/10428194.2011.572321
M3 - Article
VL - 52
SP - 1222
EP - 1229
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 7
ER -